Opioid-Related Disorders¶
Chapter 467 | Part 13: Neurologic Disorders
KEY CLINICAL POINTS¶
- Opioid use disorder is characterized by compulsive drug-seeking behavior, tolerance, and withdrawal, with significant morbidity and mortality from overdose.
- Fentanyl and its derivatives have become the leading cause of opioid-related deaths due to their high potency and frequent mixing with other drugs.
- Naloxone is the first-line treatment for opioid overdose, with dosing adjusted based on opioid type (e.g., 10 mg for fentanyl overdoses).
- Methadone and buprenorphine are FDA-approved for opioid use disorder maintenance, with buprenorphine offering safer dosing flexibility.
- Chronic opioid use disrupts neuroplasticity via cAMP-PKA-CREB pathways, contributing to tolerance and withdrawal.
1. DEFINITION & OVERVIEW¶
Opioid-related disorders encompass opioid use disorder (OUD), overdose, and associated complications. Opioids, including natural (morphine), synthetic (fentanyl), and semi-synthetic (hydromorphone) agents, act on mu-opioid receptors to produce analgesia, euphoria, and respiratory depression. The opioid epidemic has led to rising overdose deaths, with fentanyl-related fatalities increasing exponentially since 2015.
Table 467-1: Actions of Opioid Receptors¶
| RECEPTOR TYPE | ACTIONS |
|---|---|
| Mu (m) (e.g., morphine, buprenorphine) | Analgesia, reinforcement euphoria, cough and appetite suppression, decreased respirations, decreased GI motility, sedation, hormone changes, dopamine and acetylcholine release |
| Kappa (k) (e.g., butorphanol) | Dysphoria, decreased GI motility, decreased appetite, decreased respiration, psychotic symptoms, sedation, diuresis, analgesia |
| Delta (d) (e.g., etorphine) | Analgesia, euphoria, physical dependence, hormone changes, appetite suppression, dopamine release |
| Nociceptin/orphanin (e.g., buprenorphine) | Analgesia, appetite, anxiety, tolerance to opioids, hypotension, decreased GI motility, 5-HT and NE release |
1.1 Historical Context¶
Opioids have been used since ancient times (e.g., opium in China). Modern synthetic opioids emerged in the 19th century, with fentanyl developed in the 1950s. The 2010s saw a surge in illicit fentanyl production, contributing to the current overdose crisis.
1.2 Clinical Spectrum¶
Includes acute overdose, chronic use disorder, withdrawal syndrome, and long-term complications (e.g., respiratory depression, hyperalgesia, and neurocognitive deficits).
2. EPIDEMIOLOGY¶
Opioid use is widespread, with 13.5 million U.S. adults meeting DSM-5 criteria for OUD in 2022. Fentanyl-related deaths rose from 15,000 in 2017 to 76,000 in 2022. Adolescents increasingly use prescription opioids as gateway drugs, with 1.5 million U.S. teens reporting past-year use. High-potency cannabis ( ≥ 10% THC) is linked to 30–50% increased risk of psychosis in frequent users.
2.1 Demographics¶
Prevalence peaks in 20–40-year-olds; males are more likely to use illicit opioids. Adolescents using high-THC cannabis face 3–5x higher risk of psychosis. Overdose mortality is highest among middle-aged males.
2.2 Risk Factors¶
Genetic polymorphisms (e.g., mu-opioid receptor variants), polydrug use (especially with benzodiazepines), and socioeconomic factors (e.g., poverty, unemployment) increase risk. Prenatal cannabis exposure correlates with long-term cognitive deficits.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Opioids bind mu-opioid receptors, activating G protein-coupled pathways that inhibit cAMP production and hyperpolarize neurons. Chronic use leads to neuroplastic changes, including upregulation of cAMP-PKA-CREB pathways, which mediate tolerance and withdrawal. Genetic variants (e.g., mu-opioid receptor gene) enhance receptor affinity for opioids.
3.1 Receptor Mechanisms¶
Mu receptors mediate euphoria and respiratory depression; kappa receptors contribute to dysphoria and sedation. Chronic activation leads to receptor desensitization and compensatory upregulation of noradrenergic pathways.
3.2 Neuroplasticity¶
Long-term opioid exposure alters synaptic plasticity in the locus coeruleus and prefrontal cortex, contributing to hyperalgesia, craving, and relapse vulnerability.
4. CLINICAL FEATURES¶
Acute overdose presents with respiratory depression, pinpoint pupils, and unconsciousness. Withdrawal symptoms include lacrimation, rhinorrhea, muscle aches, and gastrointestinal distress. Chronic use may cause hyperalgesia, cognitive deficits, and QT prolongation.
4.1 Overdose¶
Classic signs: shallow respirations, bradycardia, hypotension, and unconsciousness. Fentanyl overdoses may present with minimal respiratory depression due to its potency.
5. DIFFERENTIAL DIAGNOSIS¶
Acute opioid overdose must be differentiated from other causes of respiratory depression (e.g., CNS depressants, poisoning). Withdrawal symptoms may mimic infectious or metabolic disorders (e.g., sepsis, hypoglycemia).
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnosis relies on clinical presentation and toxicology screens. Naloxone reversal confirms opioid overdose. Urine/blood tests identify specific opioids. For withdrawal, clinical criteria (e.g., 8–10 h post-last dose) and physical exam findings (e.g., lacrimation, rhinorrhea) are key.
Table 467-2: Management of Opioid Overdose¶
| ACTION | DETAILS |
|---|---|
| Establish airway | Intubation and mechanical ventilation may be necessary |
| Naloxone | 0.4–2.0 mg IV, IM, or endotracheal; repeat doses as needed |
| Continuous infusion | One-half to two-thirds of initial dose hourly (if not intubated) |
| Support vital functions | Oxygen, IV fluids, pressors, and cardiac monitoring |
6.1 Toxicology¶
Urine/blood tests detect opioids and their metabolites. Fentanyl detection may require specialized assays due to its rapid metabolism.
6.2 Naloxone Challenge¶
Administer 0.4–2.0 mg IV/IM to reverse respiratory depression. Dose escalation may be needed for fentanyl or buprenorphine overdoses.
7. MANAGEMENT & TREATMENT¶
Treatment includes opioid agonist/antagonist therapy (methadone, buprenorphine), naloxone for overdose, and psychosocial interventions. Detoxification with clonidine or lofexidine may be used for acute withdrawal.
7.1 Medication-Assisted Treatment (MAT)¶
Methadone (daily oral dose) and buprenorphine (sublingual) reduce cravings and withdrawal. Naltrexone (oral/injectable) blocks opioid effects but requires prior detoxification.
7.2 Withdrawal Management¶
Clonidine ( α 2 agonist) or lofexidine (less hypotensive) alleviate withdrawal symptoms. Tapering regimens for methadone may take 2–180 days.
8. PROGNOSIS & COMPLICATIONS¶
Without treatment, OUD has high relapse rates (70–90%). Complications include respiratory arrest, infectious diseases (HIV, hepatitis), and overdose mortality. Chronic use may cause hyperalgesia, cognitive deficits, and QT prolongation.
8.1 Mortality¶
Overdose accounts for 70% of opioid-related deaths. Fentanyl-related fatalities increased from 15,000 in 2017 to 76,000 in 2022.
8.2 Long-Term Effects¶
Chronic use disrupts neuroplasticity, leading to hyperalgesia, cognitive impairment, and increased risk of mental illness (e.g., depression, psychosis).
9. SPECIAL CONSIDERATIONS¶
Pregnancy: Opioid use increases neonatal abstinence syndrome risk. Pediatrics: High-potency cannabis exposure correlates with cognitive deficits. Elderly: Increased risk of respiratory depression and QT prolongation. Buprenorphine is preferred for pregnant patients due to lower fetal risk.
9.1 Pregnancy¶
Buprenorphine is safer than methadone for pregnant patients. Neonatal abstinence syndrome requires gradual tapering and supportive care.
9.2 Polydrug Use¶
Combination with benzodiazepines or stimulants significantly increases overdose risk. Naloxone may require higher doses for mixed opioid/benzodiazepine overdoses.
10. KEY POINTS & CLINICAL PEARLS¶
- Naloxone is the first-line treatment for opioid overdose, with dosing adjusted for fentanyl (up to 10 mg). 2. Buprenorphine is preferred for MAT due to its safer dosing profile. 3. Chronic opioid use disrupts cAMP-PKA-CREB pathways, contributing to tolerance and withdrawal. 4. Methadone maintenance reduces IV drug use and HIV risk by 50–70%.